News & Updates

Show Multimedia Only
Cefepime–taniborbactam bests meropenem for complicated UTI

Cefepime–taniborbactam bests meropenem for complicated UTI

10 Mar 2024 byJairia Dela Cruz

Patients with complicated urinary tract infection (UTI) may fare better with cefepime–taniborbactam than with meropenem, with the combination having been associated with much higher treatment success rates in the phase III CERTAIN-1 trial.

10 Mar 2024
TKI-ICI combo offers hope for prostate cancer patients with poor prognosis

TKI-ICI combo offers hope for prostate cancer patients with poor prognosis

29 Feb 2024 byAudrey Abella

A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.

29 Feb 2024